Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Brian Abrahams

Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment

Biogen stock tumbled Thursday — pulling Prothena stock down — on mixed test results for an updated version of its Alzheimer's treatment.

Investors Business Daily

Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock

AstraZeneca stock tumbled Wednesday after its experimental drug led to only a month's benefit over chemotherapy in lung cancer patients.

Investors Business Daily

Can Neurocrine Erase Its Recent Setbacks With This Jump To An Eight-Month High?

Neurocrine said Tuesday its experimental drug could help lower steroid use for patients with a rare, adrenal disease. NBIX stock surged.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Ambrx Biopharma Has Surged 522% This Year. But It Could Just Be Getting Started.

Ambrx is no longer flying under the radar. Instead, AMAM stock has soared 522% this year as enthusiasm grows for its cancer smart bombs.

Investors Business Daily

Regeneron Hits A New Record High On The Approval That 'Could Not Come Soon Enough'

Shares of REGN stock jumped Monday after the FDA approved Regeneron Pharmaceuticals' high-dose Eylea following a delay this summer.

Investors Business Daily

Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months

The FDA could approve Crispr Therapeutics' gene-edited sickle cell treatment as early as December. In response, CRSP stock surged Friday.

Investors Business Daily

Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near

Biogen stock rose Wednesday after the FDA posted documents that suggest the agency will approve Alzheimer's treatment Leqembi.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug

The FDA will likely reject Intercept Pharmaceuticals' highly watched liver disease treatment, analysts said Monday as ICPT stock crashed.

Investors Business Daily

Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin Pharmaceuticals

PTC stock surged Wednesday after the company unveiled promising results for its rare disease treatment, a rival to BioMarin's Kuvan.

Investors Business Daily

Sarepta Stock Catapults Higher After Eking Out A Narrow Win In Its Gene Therapy Battle

Shares of SRPT stock launched Monday after FDA advisors voted late Friday in support of a highly anticipated gene therapy from Sarepta.

Investors Business Daily

Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales

Incyte stock plummeted Tuesday as seasonality hacked at first-quarter revenue and profit with notable sales misses from Jakafi and Opzelura.

Investors Business Daily

Legend Breaks Out After Leaked Documents Show Promise In $9.6 Billion Market

Legend Biotech is staring down a $9.6 billion opportunity, an analyst said Wednesday as LEGN stock soared on positive cancer test results.

Investors Business Daily

Sarepta Tumbles As Report Of Internal FDA Strife Scorches Its Gene Therapy

Several FDA staffers were leaning toward rejecting a highly watched gene therapy from Sareptas, according to a report Thursday.

Investors Business Daily

The 21-Million-Person Market That Just Drove Intra-Cellular To A 7-Month High

Intra-Cellular said Tuesday its depression treatment succeeded in a key study, and ITCI stock broke definitively above its 200-day line.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme

Confusion over new Centers for Medicare and Medicaid Services negotiating plans sent REGN and HALO stocks tumbling Thursday.

Investors Business Daily

Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years

Intercept reached a settlement with Amneal that delays a generic version of its only product. In response, ICPT stock surged Wednesday.

Investors Business Daily

How IBD Stock Of The Day Vertex Is Stacking Up Billions In Potential Sales

Vertex is Wednesday's IBD Stock Of The Day. As the biotech eyes several blockbuster opportunities, VRTX stock is finding renewed support.

Investors Business Daily

Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges

Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

How Amgen Is Closing In On Rivals Novo Nordisk, Eli Lilly With Obesity Drug

Amgen stock jumped Tuesday on a promising update for its potential rival to obesity treatments from Novo Nordisk and Eli Lilly.

Investors Business Daily

IBD Stock Of The Day Vertex Pharma: Why Its 'Sandbox' Approach Is Unusual In Biotech

Vertex Pharmaceuticals is the IBD Stock Of The Day as VRTX stock climbs higher on expectations for its next act in gene editing.

Investors Business Daily

Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patients

Intercept Pharmaceuticals' experimental NASH treatment failed in patients with liver cirrhosis, leading ICPT stock to plummet Friday.

Investors Business Daily

Crispr Stock Jumps After Unveiling Timeline For FDA Submission Of First-Ever CRISPR Drug

Crispr said Tuesday it will begin asking the FDA to approve its gene-editing blood diseases treatment in November, and CRSP stock jumped.

Investors Business Daily

The Market Slumped Last Week; Why IBD Stock Of The Day Neurocrine Biosciences Didn't

Neurocrine Biosciences is the IBD Stock Of The Day as market uncertainty shakes plenty leading of equities — but not NBIX stock.

Investors Business Daily

15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome

In recent days, biotech stocks have slowed their early-August sprint. But not all shares are ready to hit the showers.

Investors Business Daily

Incyte Posts Strong Quarter For Cancer Drug; Here's Why Shares Crumbled

Incyte stock tumbled below its 200-day line Tuesday after sales of the company's new skin treatment lagged second-quarter expectations.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.